Non-small cell lung cancer (NSCLC) is one of two main types of lung cancer. Some lung cancers
spread to other parts of the body before they are diagnosed. A cancer that has spread is called
'metastatic'. New lung cancer treatments are being developed that directly target the gene
mutations that control how cancers grow and spread. The most important gene mutations in cancer
are called 'driver mutations'. In NSCLC this includes KRAS mutations which can be used as
targets for treatment. There are new treatments designed for lung cancers with a KRAS mutation
that are already available. And more are being developed. Treatments in development are tested
in clinical trials. There are several different phases of clinical trials that people with
cancer can take part in. This booklet aims to help patients with NSCLC understand their options
so that they can talk to their doctors nurses and medical team about their cancer and its
treatment. Table of Contents: -What is non-small cell lung cancer? -How can lung cancer
develop? -What is metastatic NSCLC? -More about genes and cancer -Oncogenes and cancer -Driver
mutations and biomarkers -How your doctor knows your cancer is KRAS-positive -More about KRAS
-What does having a KRAS-positive cancer mean for me? -Talking to your doctor about your
treatment -About clinical trials and research -Finding further information and support
